Abstract：
PURPOSE OF REVIEW:CMV DNA polymerase inhibitors such as ganciclovir and foscarnet have dramatically reduced the burden of CMV infection in the HCT recipient. However, their use is often limited by toxicities and resistance. Agents with novel mechanisms and favorable toxicity profiles are critically needed. We review recent developments in CMV antivirals and immune-based approaches to mitigating CMV infection. RECENT FINDINGS:Letermovir, an inhibitor of the CMV terminase complex, was approved in 2017 for primary CMV prophylaxis in adult seropositive allogeneic HCT recipients. Maribavir, an inhibitor of the CMV UL97 kinase, is currently in two phase 3 treatment studies. Adoptive immunotherapy using third-party T cells has proven safe and effective in preliminary studies. Vaccine development continues, with several promising candidates currently under study. No longer limited to DNA polymerase inhibitors, the prevention and treatment of CMV infections in the HCT recipient is a rapidly evolving field which should translate into improvements in CMV-related outcomes.
journal_name
Curr Hematol Malig Repjournal_title
Current hematologic malignancy reportsauthors
Hakki Mdoi
10.1007/s11899-020-00557-6subject
Has Abstractpub_date
2020-04-01 00:00:00pages
90-102issue
2eissn
1558-8211issn
1558-822Xpii
10.1007/s11899-020-00557-6journal_volume
15pub_type
杂志文章,评审abstract：:Acute myeloid leukemia (AML) is a very heterogeneous disease. Prognosis is related not only to intrinsic characteristics such as cytogenetics and molecular markers, but also the patient's ability to tolerate therapy, and treatment response. Allogeneic stem cell transplantation (allo-HCT) has been traditionally indicat...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-014-0207-4
更新日期：2014-06-01 00:00:00
abstract：:A high risk of arterial and venous thrombosis is the hallmark of chronic myeloproliferative neoplasms (MPNs), particularly polycythemia vera (PV) and essential thrombocythemia (ET). Clinical aspects, pathogenesis and management of thrombosis in MPN resemble those of other paradigmatic vascular diseases. The occurrence...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-013-0176-z
更新日期：2013-12-01 00:00:00
abstract：:Follicular lymphoma (FL), the most common indolent lymphoma, typically presents in advanced-stage disease. Currently available therapy does not generally result in a curative outcome, but survival in FL has improved since the introduction of anti-CD20 monoclonal antibody immunotherapy. The goals of treatment include p...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-011-0099-5
更新日期：2011-12-01 00:00:00
abstract：PURPOSE OF REVIEW:There are limited treatment options for relapsed/refractory classical Hodgkin lymphoma (cHL) patients who progress on brentuximab vedotin and programmed death-1 inhibitors. Camidanlumab Tesirine (Cami) is a new agent that has shown activity in multiply relapsed/refractory cHL patients. In this review,...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-021-00604-w
更新日期：2021-01-25 00:00:00
abstract：PURPOSE OF REVIEW:Antibody-drug conjugates are a new class of therapeutic agents in the treatment of B cell malignancies. In this review, we summarize the recent developments of polatuzumab vedotin in the treatment of relapsed or refractory diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL). RECENT FIN...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-020-00572-7
更新日期：2020-04-01 00:00:00
abstract：PURPOSE OF REVIEW:Over the past two decades, the introduction of tyrosine kinase inhibitors (TKIs) has transformed the treatment of chronic myeloid leukemia (CML). With four agents currently approved for frontline use in chronic-phase (CP) disease, it follows that treatment decision-making has been rendered more challe...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-018-0449-7
更新日期：2018-06-01 00:00:00
abstract：PURPOSE OF REVIEW:The Choosing Wisely® initiative, led by the American Board of Internal Medicine Foundation in collaboration with national professional medical societies, aims to help patients choose care that is essential, free from harm, and evidence-based. The American Society of Hematology has advocated practices ...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-020-00593-2
更新日期：2020-08-01 00:00:00
abstract：:The diagnosis of lymphoma in pregnant patients poses a therapeutic challenge necessitating consideration of the developing fetus without compromise of therapy with curative potential for the mother. The decision to initiate therapy during pregnancy is heavily influenced by fetal, maternal, and disease-related factors,...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-017-0386-x
更新日期：2017-06-01 00:00:00
abstract：:High-dose chemotherapy with autologous stem cell transplantation (ASCT) has been shown to improve survival in patients with multiple myeloma in randomized trials and is the standard of care for eligible patients. Recent randomized trials suggest a survival benefit with tandem ASCT, notably for patients failing to achi...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-007-0017-z
更新日期：2007-05-01 00:00:00
abstract：:In recent years, the treatment of multiple myeloma has undergone significant changes. The availability of novel agents bortezomib, thalidomide and lenalidomide considerably improved the outcome of patients. The advantages related to the use of novel agents have been shown in various studies in patients eligible and in...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-013-0177-y
更新日期：2013-12-01 00:00:00
abstract：:The DNA hypomethylating agents (HMAs) azacitidine and decitabine are currently the most frequently administered disease-modifying therapies for patients with higher-risk myelodysplastic syndromes (MDS). However, azacitidine and decitabine are not curative, the median response duration is 11-15 months, and only 10-20 %...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-015-0273-2
更新日期：2015-09-01 00:00:00
abstract：:Multiple myeloma is a disorder of terminally differentiated plasma cells, characterized by immune dysfunction, deregulated signaling within the bone marrow stromal compartment, and a microenvironment that fosters immunosuppression. Immunomodulatory techniques, such as allogeneic hematopoietic stem cell transplant (all...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-015-0283-0
更新日期：2015-12-01 00:00:00
abstract：PURPOSE OF REVIEW:This review discusses the current standard of care for incorporation of FLT3 TKIs and HCT into the treatment of FLT3-ITD AML. Additionally, this review provides an approach to the patient with relapsed/refractory disease. RECENT FINDINGS:Over the last decade, the routine use of HCT as consolidative t...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-020-00558-5
更新日期：2020-02-01 00:00:00
abstract：:Patients with acute leukemia who undergo hematopoietic stem cell transplantation (HSCT) are susceptible to malnutrition caused by several factors including intensive cytotoxic therapy. This paper discusses the significance of malnutrition in these patients and provides an overview of nutrition therapy by the oral, ent...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-996-0007-6
更新日期：2006-09-01 00:00:00
abstract：:Progress in the understanding of the biology of chronic lymphocytic leukemia and in the development of new and effective therapies has generated a shift in treatment paradigms within only a few years. Traditional chemotherapy agents such as alkylators or nucleoside analogs are rapidly being replaced by combination reg...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-006-0006-7
更新日期：2006-12-01 00:00:00
abstract：:Chronic myelomonocytic leukemia is a clonal malignancy of the ageing hematopoietic stem cell characterized by a biased differentiation leading to persistent monocytosis and inconstant hypersensitivity of myeloid progenitors to granulo-monocyte colony-stimulating factor (GM-CSF). Cytogenetic abnormalities identified in...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-014-0225-2
更新日期：2014-12-01 00:00:00
abstract：:Patients with hematologic malignancies are increasing being prescribed oral anticancer medications (OAMs) and/or biologics. These newer targeted OAMs are associated with a host of practical and pharmacoeconomic implications for patients and healthcare providers. Issues such as safety, procurement challenges, and the n...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-016-0325-2
更新日期：2016-08-01 00:00:00
abstract：:No therapy is uniformly effective in the management of immunoglobulin light chain amyloidosis (AL amyloidosis). Despite the common generalization, therapy is highly effective. Options available to patients with AL amyloidosis include high-dose therapy, but this is applicable to only about one fourth of patients. Thera...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-009-0013-6
更新日期：2009-04-01 00:00:00
abstract：PURPOSE OF REVIEW:Social media has revolutionized the access and exchange of information in healthcare. The microblogging platform Twitter has been used by blood and marrow transplant physicians over the last several years with increasing enthusiasm. We review the adoption of Twitter in the transplant community and its...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-018-0434-1
更新日期：2018-02-01 00:00:00
abstract：PURPOSE OF REVIEW:Myelodysplastic syndrome (MDS) is a clinically and molecularly heterogeneous disease, which primarily occurs in older adults. Although hypomethylating agents have survival benefit and are the current standard of care, many MDS patients will not garner a response from therapy. For those who do respond,...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-018-0477-3
更新日期：2018-12-01 00:00:00
abstract：PURPOSE OF REVIEW:Passive immunotherapy with therapeutic monoclonal antibodies (mAbs) has revolutionized the treatment of cancer, especially hematological malignancies over the last 20 years. While use of mAbs has improved outcomes, development of resistance is inevitable in most cases, hindering the long-term survival...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-019-00542-8
更新日期：2019-10-01 00:00:00
abstract：:The prognosis value of interim positron emission tomography (PET) remains controversial in diffuse large B-cell lymphoma (DLBCL) patients because of the absence of consensus on criteria able to early identify good and bad responders to treatment. Visual interpretation using the International Harmonization Project (IHP...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-012-0129-y
更新日期：2012-09-01 00:00:00
abstract：PURPOSE OF REVIEW:The recent development of brentuximab vedotin (BV), an antibody-drug conjugate targeting CD30-positive cells, has led to therapeutic advances in the treatment of T cell lymphomas. In this review, we discuss key studies of BV in peripheral T cell lymphoma (PTCL) and cutaneous T cell lymphoma (CTCL) and...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-020-00561-w
更新日期：2020-02-01 00:00:00
abstract：:Cutaneous T-cell lymphoma (CTCL) is a malignancy derived from a clonal population of mature, skin-homing lymphocytes. In the skin, the CTCL cells are associated with the Langerhans cells and respond to protumor cytokines. In turn, they upregulate T-cell receptor-dependent signaling pathways and subsequently demonstrat...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-007-0037-8
更新日期：2007-10-01 00:00:00
abstract：:Advances in drug discovery have led to the use of effective targeted agents in the treatment of hematologic malignancies. Drugs such as proteasome inhibitors in multiple myeloma and tyrosine kinase inhibitors in chronic myeloid leukemia and non-Hodgkin lymphoma have changed the face of treatment of hematologic maligna...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-017-0369-y
更新日期：2017-06-01 00:00:00
abstract：:The advent of social media has led to the ability for individuals all over the world to communicate with each other, in real time, about mutual topics of interest in an unprecedented manner. Recently, the use of social media has increased among people interested in healthcare and medical research, particularly in the ...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-015-0287-9
更新日期：2015-12-01 00:00:00
abstract：PURPOSE OF REVIEW:This article will review the use of anti-CD19 CAR-T therapy used in relapsed/refractory diffuse large B cell lymphoma. RECENT FINDINGS:The clinical outcomes, safety analysis, and other relevant considerations will be discussed with an emphasis on the most recently published data regarding the ZUMA-1,...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-018-0482-6
更新日期：2018-12-01 00:00:00
abstract：PURPOSE OF REVIEW:Social media has dramatically changed the access and exchange of information in healthcare and beyond. A variety of platforms and resources exist allowing blood and marrow transplant providers, researchers, and patients to interact. We review the adoption of social media by the transplantation communi...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-018-0487-1
更新日期：2018-12-01 00:00:00
abstract：:The peripheral T cell lymphomas (PTCLs) are a heterogeneous group of neoplasms for which standardized treatment approaches remain elusive. A number of new therapeutic agents have become available, of which monoclonal antibodies (MAbs) represent a powerful tool for targeted treatment of PTCLs. Therapeutic MAbs vary in ...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-015-0290-1
更新日期：2015-12-01 00:00:00
abstract：PURPOSE OF REVIEW:Ruxolitinib is the first FDA-approved JAK inhibitor for the treatment of myeloproliferative neoplasms and is an effective means of controlling symptom burden and improving splenomegaly. However, a majority of patients will develop disease progression with long-term use. Fedratinib, momelotinib, and pa...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-020-00596-z
更新日期：2020-12-01 00:00:00
